AICENNA, Digital Twin.
Through AI, IoT
& Genomics.
AICENNA is a US-based healthcare technology company building the future of preventive medicine through Digital Twin technology—integrating real-time biosensing, genomics, and AI-driven simulations.
AICENNA, a subsidiary of Elixem Holdings LLC, is headquartered in the US with strategic leadership and clinical infrastructure in Dubai and Pakistan. Our goal is to transform reactive healthcare into a personalized, proactive, and predictive system.
We’re here to change to the way healthcare works by making it smarter, earlier and more personal. Using AI, connected devices, and your unique genetic insights, we help spot health risks before they become problems. It’s about giving people and their doctors the tools to stay ahead of illness, not just treat it. Our vision is a future where care is continuous, tailored to you, and build to keep you well, not just get you better.
An AI-powered replica of
an individual’s health profile using
• IoT Integration & Data Lake
• AI-powered Digital Twin
• MedAI Studio for Custom AI
• HealthBot (AI Assistant)
• Cloud & On-device Architecture
Hospitals & Clinics
Hospitals & Clinics
Insurance Providers
Insurance Providers
Genomic Research Labs
Genomic Research Labs
Health-Tech Consumers
Health-Tech Consumers
Investment & Ask
We are raising $3 million in pre-launch equity funding, offering a 15% stake at a $20M post-money valuation. This capital provides an estimated 18-month runway, covering operational cost of 167K/month through end of 2026.
The platform launches in Q3 2025, with revenue generation starting January 2026. We project to reach $1.5 million in a Year 1(2026), and scale to $5.6 million by 2028, driven by SaaS subscriptions, clinical partnerships and B2B licensing.
With a gross margin stabilizing around 66%, the business model becomes cash-flow efficient early, enabling compounding growth.
Why Invest
- ✅ First-of-its-kind one-window platform combing biosensing, genomics, AI and clinical insight
- ✅ Customizable, scalable and regulation-ready
- ✅ Built-in MedAI Studio empowers real-time model evolution by clinicians
- ✅ Clear path to revenue via tiered pricing and enterprise integration
- ✅ Positioned to lead the next wave in AI-powered preventive care
- ✅ Pre-launch equity at $2 share, 15% stake open
-
Stem cell therapy pioneer and regenerative medicine expert. Fellow of A4M and ABRM.
-
-
Finance and project strategy veteran with over 30 years across public and private sectors.
-
-
Media Expert with 20+ years of experience, having diverse profile of global reach & international relations.
-
• Digital Twin Simulation
• IoT + Data Integration
• HealthBot AI Assistant
• MedAI Studio Launch
• Billing & Commercialization Modules
• Pilot Deployments (Hospitals, Labs, Insurance)